Purpose Recurrent glioblastoma multiforme (GBM) is incurable with current therapies. Biallelic
mismatch repair deficiency (bMMRD) is a highly penetrant childhood cancer syndrome …

Background Detection of the BRAF V600E mutation in pediatric low-grade glioma has been
associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (…

Purpose Recent genomic approaches have suggested the existence of multiple distinct
subtypes of medulloblastoma. We studied a large cohort of medulloblastomas to determine how …

Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated
with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive …

While molecular subgrouping has revolutionized medulloblastoma classification, the extent
of heterogeneity within subgroups is unknown. Similarity network fusion (SNF) applied to …

Pediatric glioblastomas (GBM) including diffuse intrinsic pontine gliomas (DIPG) are
devastating brain tumors with no effective therapy. Here, we investigated clinical and biological …

Medulloblastoma is a malignant childhood brain tumour comprising four discrete subgroups.
Here, to identify mutations that drive medulloblastoma, we sequenced the entire genomes …

Diffuse intrinsic brainstem gliomas constitute 15–20% of all CNS tumours in children, and are
the main cause of death in children with brain tumours. Many clinical trials have been done …

We present an extensive assessment of mutation burden through sequencing analysis of >81,000
tumors from pediatric and adult patients, including tumors with hypermutation caused …

Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of
children, with no effective treatment and near 100% fatality. The failure of most therapies can …